Physician profile
Elyssa Foster
NPI 1528776531
$13,893.60
in general payments reported to CMS, 2019-2025
28 companies · $7,215 in 2025
The $7,215 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,154 · 2024: $4,525 · 2025: $7,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,448 · Honoraria: $3,200 · Travel and Lodging: $1,535 · Consulting Fee: $1,320 · Education: $388 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,448.03 |
| Honoraria | $3,200.00 |
| Travel and Lodging | $1,534.54 |
| Consulting Fee | $1,320.00 |
| Education | $387.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $5,009.22 | 2025 | |
| Incyte Corporation | $1,839.22 | 2023-2024 | Jakafi |
| Janssen Biotech, INC. | $1,512.29 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Adaptive Biotechnologies Corporation | $1,054.66 | 2023-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $699.23 | 2023-2024 | |
| Daiichi Sankyo INC. | $475.11 | 2024-2025 | Vanflyta |
| Kite Pharma, INC. | $389.61 | 2024-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $338.10 | 2023-2024 | Imfinzi, Enhertu |
| Janssen Scientific Affairs, LLC | $318.39 | 2023-2025 | Carvykti, Darzalex, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $283.99 | 2023-2025 | Livtencity |
| Astellas Pharma US INC | $234.16 | 2024-2025 | Cresemba, Xospata |
| Abbvie INC. | $219.18 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.98 | 2024 | Onureg, Opdivo |
| Genmab U.S., INC. | $179.24 | 2023-2025 | Epkinly |
| Legend Biotech USA INC. | $153.61 | 2024-2025 | Carvykti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $148.50 | 2024 | Sir-Spheres Microspheres |
| Syndax Pharmaceuticals, INC. | $145.28 | 2025 | Revuforj |
| Jazz Pharmaceuticals INC. | $125.57 | 2023 | |
| Sobi, INC | $119.05 | 2023 | |
| Blueprint Medicines Corporation | $116.15 | 2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $113.64 | 2023 | Imbruvica |
| Glaxosmithkline, LLC. | $110.76 | 2024 | Ojjaara |
| Bard Peripheral Vascular, INC. | $31.03 | 2025 | Trek |
| Celgene Corporation | $23.24 | 2025 | Breyanzi |
| Merck Sharp & Dohme LLC | $21.98 | 2025 | Prevymis |
| Recordati_rare_diseases_inc. | $20.89 | 2023 | Panhematin |
| Karyopharm Therapeutics INC. | $15.84 | 2023 | Xpovio |
| Iovance Biotherapeutics, INC. | $14.68 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyssa Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.